BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 81 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $930,981 | -32.0% | 324,291 | +19.6% | 0.00% | – |
| Q2 2023 | $1,369,595 | +168.0% | 271,207 | +0.3% | 0.00% | – |
| Q1 2023 | $511,108 | +107050.5% | 270,428 | +1.9% | 0.00% | – |
| Q4 2022 | $477 | -99.9% | 265,290 | +0.3% | 0.00% | – |
| Q3 2022 | $447,000 | -26.2% | 264,547 | +7.2% | 0.00% | – |
| Q2 2022 | $606,000 | -49.3% | 246,708 | -42.9% | 0.00% | – |
| Q1 2022 | $1,196,000 | -43.3% | 432,024 | +9.1% | 0.00% | – |
| Q4 2021 | $2,111,000 | -28.7% | 396,167 | +13.2% | 0.00% | – |
| Q3 2021 | $2,960,000 | -32.5% | 349,980 | -2.7% | 0.00% | -100.0% |
| Q2 2021 | $4,383,000 | -39.3% | 359,602 | +20.9% | 0.00% | 0.0% |
| Q1 2021 | $7,215,000 | -16.6% | 297,437 | +10.2% | 0.00% | 0.0% |
| Q4 2020 | $8,651,000 | +15.5% | 269,925 | +9.0% | 0.00% | 0.0% |
| Q3 2020 | $7,488,000 | -2.3% | 247,726 | +36.3% | 0.00% | -50.0% |
| Q2 2020 | $7,663,000 | +239.8% | 181,764 | +101.1% | 0.00% | +100.0% |
| Q1 2020 | $2,255,000 | – | 90,397 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
| Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
| Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
| Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
| Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
| DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
| RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
| Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
| MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
| K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |